7 Nov 2017 10:00
7 November 2017
Grant of Share Options
Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"), announces that, on 6 November 2017, the following Directors were granted share options over a total of 122,995 ordinary shares of 0.1 pence each ("Ordinary Shares"), granted under the Clinigen Group Long Term Incentive Plan 2015. The options are nil cost options intended to vest on 16 October 2020 subject to the achievement of certain performance criteria.
The additional share options granted to Shaun Chilton are in relation to the completion of the acquisition of Quantum Pharma plc.
Director/PDMR | Number of share options granted | Total number of share options now held |
| Total number of ordinary shares now held | Total number of ordinary shares (excluding share options) as % issued share capital |
Shaun Chilton | 43,630 | 318,420 |
| 312,943 | 0.26% |
Chris Rigg | 79,365 | 79,365 |
| 6,563 | 0.01% |
-Ends-
Contact details
Clinigen Group plc | Tel: +44 (0) 1283 495010 |
Shaun Chilton, Group Chief Executive Officer | |
Martin Abell, Group Chief Financial Officer | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) James Black / Tom Ballard (Corporate Broking) | |
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas / Jack Wood | |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Alex Shaw / Deborah Bell | Email: clinigen@instinctif.com |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
For more information, please visit www.clinigengroup.com